UCLA Geffen School of Medicine, Los Angeles, CA, USA.
The Fenway Institute, Boston, MA, USA.
AIDS Behav. 2021 Jun;25(6):1873-1883. doi: 10.1007/s10461-020-03117-4. Epub 2021 Jan 1.
We conducted a pilot randomized controlled trial of a social network-based intervention to promote PrEP adherence among transgender women (TW) in Lima, Peru. We enrolled 89 TW from six social networks and cluster-randomized them 1:1 to standard of care (n = 44) or the TransPrEP intervention (n = 45). Core workshops discussed strategies to support PrEP adherence and defined group adherence objectives. Maintenance workshops discussed participants' experiences taking PrEP and collective adherence goals. At 3-month follow-up, we evaluated 40 participants and obtained 29 hair samples for tenofovir level measurements. Though no significant differences were observed, 36.4% (4/11) of participants of TransPrEP participants and 10.0% (1/10) of control participants had tenofovir levels > 0.023 ng/mg, consistent with ≥ 4 doses per week. 81.8% (9/11) of intervention and 40.0% (4/10) of control participants had any detectable tenofovir in their hair. Pilot assessment of our network-based intervention suggested a trend towards improved PrEP adherence, measured objectively, for TW in Peru.
我们在秘鲁利马进行了一项基于社交网络的干预措施的试点随机对照试验，以促进跨性别女性（TW）接受 PrEP。我们从六个社交网络中招募了 89 名 TW，并将他们 1:1 随机分为标准护理组（n=44）或 TransPrEP 干预组（n=45）。核心研讨会讨论了支持 PrEP 依从性的策略，并确定了小组依从性目标。维护研讨会讨论了参与者服用 PrEP 的经验和集体依从性目标。在 3 个月的随访中，我们评估了 40 名参与者，并获得了 29 份头发样本进行替诺福韦水平测量。尽管没有观察到显著差异，但 36.4%（4/11）的 TransPrEP 参与者和 10.0%（1/10）的对照组参与者的替诺福韦水平>0.023ng/mg，与每周至少 4 剂一致。81.8%（9/11）的干预组和 40.0%（4/10）的对照组参与者的头发中检测到任何可检测到的替诺福韦。对我们基于网络的干预措施的初步评估表明，秘鲁的 TW 接受 PrEP 的依从性有改善的趋势，这是通过客观测量得出的。
